Reardon, D. A., Schuster, J., Tran, D. D., Fink, K. L., Nabors, L. B., Li, G., … Sampson, J. H. (2015). ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. In Journal of Clinical Oncology (Vol. 33, pp. 2009–2009). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.2009

Reardon, David A., James Schuster, David Dinh Tran, Karen L. Fink, Louis B. Nabors, Gordon Li, Daniela Annenelie Bota, et al. “ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.” In Journal of Clinical Oncology, 33:2009–2009. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2009.

Reardon DA, Schuster J, Tran DD, Fink KL, Nabors LB, Li G, et al. ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2009–2009.

Reardon, David A., et al. “ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 2009–2009. Crossref, doi:10.1200/jco.2015.33.15_suppl.2009.

Reardon DA, Schuster J, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, Green JA, Yellin MJ, Turner CD, Davis TA, Sampson JH. ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2009–2009.